Zevra Therapeutics Inc.
ZVRA | NASDAQ
$11.67
$0 (0.00%)
Sep 22, 2026, 12:51 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | 6.40 | -3.66 | -5.04 | -5.88 | -4.13 | -3.49 |
PEG Ratio | -0.04 | -0.05 | -0.08 | 0.09 | 0.12 | 0.05 |
PS Ratio | 4.65 | 16.34 | 8.46 | 15.58 | 9.05 | 3.36 |
PB Ratio | 3.20 | 9.72 | 3.75 | 2.11 | 2.04 | -0.67 |
P/FCF Ratio | -203.69 | -5.54 | -6.86 | -8.42 | 25.08 | -22.61 |
P/OCF Ratio | -310.13 | -5.54 | -6.92 | -8.46 | 24.84 | -22.99 |
OCF/S Ratio | -1.50 | -295.04 | -122.12 | -184.20 | 36.44 | -14.59 |
Debt / Equity Ratio | 0.41 | 1.52 | 0.71 | 0.25 | 0.01 | -1.06 |
Quick Ratio | 5.63 | 2.47 | 0.85 | 7.72 | 27.20 | 1.11 |
Current Ratio | 5.68 | 2.53 | 1.18 | 7.72 | 27.20 | 1.11 |
Asset Turnover | 0.37 | 0.13 | 0.16 | 0.09 | 0.22 | 1.19 |
Interest Coverage | -0.53 | -11.84 | -33.05 | -127.06 | 20.56 | -0.79 |
Return on Equity | 53.82% | -266% | -74.44% | -35.64% | -6.73% | 19.21% |
Return on Assets | 29.23% | -59.23% | -26.72% | -23.21% | -6.44% | -113.84% |
Return on Invested Capital | -1.65% | -60.22% | -36.25% | -39.20% | 5.99% | -122.62% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 84.52% | 68.59% | 89.28% | 97.82% | 92.81% | 90.18% |
Net Profit Margin | 78.17% | -446.85% | -167.69% | -263.48% | -29.86% | -96.03% |
Pretax Profit Margin | 81.41% | -381.75% | -167.69% | -263.80% | -29.74% | -96.28% |
Operating Profit Margin | -3.98% | -368.47% | -180.63% | -418.91% | 26.98% | -42.21% |
FCF Margin | -2.29% | -295.04% | -123.20% | -185.12% | 36.08% | -14.84% |
EBITDA Margin | 92.71% | -323.56% | -158.56% | -251.22% | -27.53% | -40.87% |
Add to Watchlist
Select watchlists to add or remove ZVRA